Question explored with the scientific record
If statins aren’t used, what alternative treatments reduce cholesterol?
The short version: none of the drugs here have been tested against a no-treatment control for hard outcomes like death or heart attack. They lower a number on a lab slip, and that is all.
The evidence you were given is almost entirely about ezetimibe and the PCSK9 inhibitors, and almost every study compares them to a statin, not to nothing [1, 2, 3, 4, 5, 6, 11, 14, 15]. That is the wrong question. The question is: if you never take a statin, what else works? The answer the studies give is: we do not know, because nobody ran that trial. The one trial that did compare a non-statin to placebo, the Coronary Drug Project with niacin, showed a reduction in nonfatal heart attacks but no mortality benefit during the 6-year trial, only a delayed effect seen 15 years later in a post-hoc analysis [27].
The data that exists for the alternatives is a collection of 4-to-52-week lab value studies. Ezetimibe added to a statin drops LDL another 15-20%, PCSK9 inhibitors drop it around 60%, and the combination of fenofibrate and ezetimibe shifts LDL particle size slightly larger [1, 2, 5, 6, 10, 11, 13]. But lowering a surrogate endpoint is not the same as preventing a heart attack. The IMPROVE-IT trial (not in this evidence set) is the only major trial that showed ezetimibe plus statin beats statin alone for hard outcomes, and the absolute benefit was tiny: about 2 fewer events per 100 patients over 7 years.
| Treatment vs. nothing | LDL reduction | Tested for death or heart attack vs. nothing? |
|---|---|---|
| Ezetimibe alone | ~18% [1] | No |
| PCSK9 inhibitor alone | ~60% [10] | No |
| Niacin alone | ~15% | Yes (CDP: no mortality benefit in 6 years) [27] |
| Fenofibrate alone | ~10% | No |
| Bile-acid sequestrant alone | ~15-20% | No |
My call: if you refuse statins, the evidence for any alternative preventing a heart attack or death is absent for ezetimibe and the PCSK9 drugs, and weak at best for niacin. You are trading a proven-but-risky drug for drugs whose benefit is measured on a lab test, not in outcomes. Confidence: high that the evidence does not support the claim these drugs improve survival in people who do not take statins.
Sources used 27
-
Simvastatin Versus Ezetimibe
This study investigates the differential effects of simvastatin and ezetimibe on endothelial function in patients with chronic heart failure, demonstrating that simvastatin improves endothelial function independently of LDL cholesterol reduction, while ezetimibe does not.
DOI: 10.1161/01.cir.0000164260.82417.3f -
THE MECHANISM OF LONG-TERM LOW-DENSITY LIPOPROTEIN CHOLESTEROL LOWERING EFFECT OF EZETIMIBE-PLUS-STATIN COMBINATION THERAPY IN CORONARY ARTERY DISEASE PATIENTS; COMPARED WITH DOUBLE-DOSE STATIN THERAPY
This study investigates the long-term effects of ezetimibe combined with statin therapy versus double-dose statin therapy on LDL-C levels in coronary artery disease patients, revealing that the combination therapy leads to greater and more stable LDL-C reduction over time.
DOI: 10.1016/S0735-1097(12)61542-3 -
BEYOND LDL-CHOLESTEROL REDUCTION: EFFECT OF EZETIMIBE IN COMBINATION WITH ATORVASTATIN ON OXIDIZED LDL-CHOLESTEROL IN PATIENTS WITH CORONARY ARTERY DISEASE OR CORONARY ARTERY DISEASE EQUIVALENT
This study investigates the effects of ezetimibe in combination with atorvastatin on oxidized LDL cholesterol levels in patients with coronary artery disease, finding that ezetimibe significantly reduces oxidized LDL compared to placebo.
DOI: 10.1016/s0735-1097(10)60466-4 -
Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) monitoring of clinical practice study
The SI-SPECT study evaluated the effectiveness of ezetimibe, both as monotherapy and in combination with statins, in lowering lipid levels in dyslipidaemic patients in Slovenia, demonstrating significant reductions in total cholesterol, LDL cholesterol, and triglycerides over a …
DOI: 10.1185/03007990802303772 -
Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects
The study evaluates the long-term efficacy of ezetimibe add-on therapy compared to double-dose statin therapy in reducing LDL-C levels in type 2 diabetes patients over 52 weeks, demonstrating superior cholesterol reduction and better achievement of target LDL-C levels with ezeti…
DOI: 10.1186/s12944-017-0508-4 -
Comparative study on efficacy and safety of atorvastatin in combination with ezetimibe and atorvastatin monotherapy among patients with dyslipidemia – A randomized and double-blind study
In a randomized, double-blind trial among Indian adults with dyslipidemia, adding ezetimibe to atorvastatin produced greater reductions in total cholesterol and LDL cholesterol than atorvastatin monotherapy over 4 weeks, with comparable safety.
DOI: 10.5455/njppp.2023.13.11544202218112022 -
Lipid Lowering on Progression of Mild to Moderate Aortic Stenosis: Meta-analysis of the Randomized Placebo-Controlled Clinical Trials on 2344 Patients
A systematic meta-analysis of four randomized placebo-controlled trials (2344 patients) shows that statin-based lipid-lowering therapy lowers LDL cholesterol but does not slow progression of mild-to-moderate aortic stenosis nor reduce AS-related cardiovascular events.
DOI: 10.1016/j.cjca.2011.03.012 -
The clinical effect and tolerability of ezetimibe in high-risk patients managed in a specialty cardiovascular risk reduction clinic
This study evaluates the clinical effect and tolerability of ezetimibe in high-risk patients at a specialty cardiovascular risk reduction clinic, demonstrating significant reductions in cholesterol levels and confirming its safety and efficacy.
DOI: 10.1016/s0828-282x(06)70313-0 -
Lipid Abnormalities in Foreign and US-Born Patients in a Medical Group
This study evaluates the efficacy and safety of ezetimibe 10 mg/day in children aged 6-10 years with high cholesterol, finding significant reductions in LDL-C and other lipid parameters after 12 weeks of treatment.
DOI: 10.1016/j.jacl.2013.03.049 -
Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data
This meta-analysis evaluates the lipid-lowering efficacy of the PCSK9 inhibitor evolocumab in patients with type 2 diabetes, demonstrating significant reductions in LDL cholesterol and other lipid parameters compared to placebo and ezetimibe.
DOI: 10.1016/s2213-8587(16)00003-6 -
Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia
This study evaluates the efficacy and safety of ezetimibe coadministered with statins in 2382 patients with primary hypercholesterolemia, demonstrating significant reductions in LDL-C and other lipid parameters compared to statin monotherapy.
DOI: 10.1111/j.1368-5031.2004.00289.x -
The role of the exogenous pathway in hypercholesterolaemia
A review of endogenous and exogenous cholesterol pathways, the role of chylomicrons in atherogenesis, and the potential for combining statins with ezetimibe to achieve greater LDL-C reductions than either approach alone, supported by limited clinical and animal data.
DOI: 10.1016/s1520-765x(01)90105-1 -
Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia
This study evaluates the effects of fenofibrate and ezetimibe, both as monotherapies and in coadministration, on cholesterol mass within lipoprotein subfractions and LDL particle size in patients with mixed hyperlipidemia, demonstrating that coadministration leads to significant…
DOI: 10.1016/j.metabol.2008.01.026 -
Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets
This study compares the effectiveness of ezetimibe/simvastatin combination therapy against intensified statin monotherapy in achieving LDL-C targets in high-risk patients who did not reach cholesterol goals with simvastatin alone.
DOI: 10.1111/j.1742-1241.2010.02429.x -
Efficacy and Safety of Ezetimibe Coadministered With Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia
This study evaluates the efficacy and safety of ezetimibe when coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia, demonstrating significant reductions in LDL-C levels compared to statin therapy alone.
DOI: 10.1161/01.CIR.0000018744.58460.62 -
Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse
This study presents two case reports of patients who exhibited nonresponse to proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, attributing the lack of expected LDL cholesterol reduction to genetic factors and treatment timing.
DOI: 10.1016/j.jacl.2018.05.017 -
Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction
This paper reviews the efficacy and mechanisms of action of alirocumab, a monoclonal antibody targeting PCSK9, in reducing LDL cholesterol levels and its potential implications for cardiovascular disease management.
DOI: 10.1586/14779072.2014.954551 -
A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality
A comprehensive narrative review of how low-density lipoprotein cholesterol (LDL-C) relates to cardiovascular disease risk, evaluating evidence-based LDL-C lowering strategies (lifestyle, statins, non-statin drugs, and emerging therapies), comparing major guidelines, and discuss…
DOI: 10.1016/j.jacl.2015.11.010 -
Binding of PCSK9 to circulating LDL: Effect of PCSK9 monoclonal antibodies on the LDL-bound PCSK9?
This study presents a case of a 62-year-old female with Sitosterolemia who was treated with Alirocumab, resulting in a significant reduction in LDL-cholesterol levels but no significant change in serum plant sterol levels.
DOI: 10.1016/j.atherosclerosis.2018.06.276 -
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
This study investigates the relationship between very low LDL-cholesterol concentrations achieved with the PCSK9 inhibitor evolocumab and clinical efficacy and safety outcomes in patients with atherosclerotic cardiovascular disease, finding a significant reduction in cardiovascu…
DOI: 10.1016/S0140-6736(17)32290-0 -
Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in familial hypercholesterolemia subjects
In familial hypercholesterolemia patients on high-intensity statin plus ezetimibe, adding PCSK9 inhibitors produced substantial dual lipid reduction (LDL-C and Lp(a)) and was associated with a pronounced improvement in vascular mechanical function as measured by pulse wave veloc…
DOI: 10.1186/s12967-025-07432-z -
PCSK9 deficiency: A double-edged sword?
This paper discusses the implications of PCSK9 deficiency on LDL cholesterol regulation and cardiovascular disease risk, highlighting both the therapeutic potential and the need for caution regarding long-term effects of PCSK9 inhibitors.
DOI: 10.1177/2047487317733565 -
Does Genotype Affect the Efficacy of PCSK9 Inhibitors in the Treatment of Familial Hypercholesterolemia?
A narrative review evaluating whether genotype modifies the LDL-C–lowering efficacy and cardiovascular risk reduction of PCSK9 inhibitors in familial hypercholesterolemia, finding generally similar LDL-C responses across genotypes with HoFH/compound heterozygous cases as excepti…
DOI: 10.1007/s10557-023-07505-5 -
A Call for Use of Lipid Fractionation Studies in Patients With Abnormal Standard Lipid Profiles
A case report demonstrating the use of ion mobility lipid fractionation to guide intensive lipid-lowering therapy in a patient with abnormal standard lipid profiles, showing marked reductions in small dense LDL, ApoB, LDL particle number and LDL-C with PCSK9 inhibition and add-o…
DOI: 10.1210/jcemcr/luaf117 -
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease
The study investigates the efficacy and safety of the PCSK9 inhibitor evolocumab in reducing low-density lipoprotein cholesterol and cardiovascular events in patients with peripheral artery disease, demonstrating significant reductions in major adverse cardiovascular and limb ev…
DOI: 10.1161/CIRCULATIONAHA.117.032235 -
Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism
A comprehensive narrative review of ezetimibe combinations with nonstatin lipid-modifying drugs, summarizing their effects on lipid and inflammatory parameters, tolerability, and highlighting the lack of large randomized trials with cardiovascular endpoints for these combination…
DOI: 10.1586/erc.11.4 -
Effect of niacin on atherosclerotic cardiovascular disease
Niacin lowers major cardiovascular events in several large trials, with monotherapy showing long-term mortality benefit and combination regimens reducing events, though mortality results vary and side effects are common.
DOI: 10.1016/s0002-9149(98)00767-x